ArQule, Inc. (ARQL - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 16.4% in the past one-month time frame.
The move came after the company announced that the first patient was dosed in registrational MOSIAC trial of Miransertib for the treatment of proteus syndrome and PIK3CA-related overgrowth spectrum.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
ArQule currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Investors interested in the Medical - Drugs industry may consider a better-ranked stock like KemPharm, Inc. (KMPH - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ARQL going up? Or down? Predict to see what others think:Up or Down
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>